Adaptive Biotechnologies has built a robust immune medicine platform capable of aiding researchers and pharma partners across the immuno-oncology development spectrum—from early pre-clinical development through large scale registrational clinical trials. Adaptive’s core immunosequencing technology sequences T-cell receptors (TCR) and B-cell receptors (BCR) at high throughput, generating in-depth immune repertoire profiles. These rich datasets can be applied to answer key questions during drug development including determining the mechanism of action of a drug, identifying potential biomarkers of response, monitoring pharmacodynamics and kinetics, and predicting potential adverse events.
Additionally, Adaptive has developed technologies capable of pairing TCR alpha and beta chains, mapping TCRs to their cognate antigens, and characterizing the ability of TCRs to bind their target. This webinar will provide an overview of Adaptive’s suite of technologies and how attendees can use these tools to provide high-quality data to inform decision making and successfully advance their drug development projects.
This content applies to those across biotechnology research, pharmaceutical manufacturing and cell therapy development and/or manufacturing with roles spanning science and laboratory, research and business development.
Patrick Raber, PhD, is an immunologist with more than 12 years of research experience and an expert in the field of immunosequencing. His current role as senior director at Adaptive is focused on incorporating immunosequencing into translational research and clinical trials for Adaptive’s biopharmaceutical and academic partners. He specializes in experimental design, data analysis and data interpretation. Patrick earned a PhD in microbiology, immunology, and parasitology from the LSU Health Sciences Center in New Orleans, LA.
Erik Yusko, PhD, has spent almost a decade in various roles at Adaptive, most recently building sophisticated drug discovery capabilities and advancing partnerships with pharmaceutical manufacturers. He developed models for tracking repertoire dynamics in response to various therapies as computational biologist, advancing our understanding of how immunotherapies modulate the immune response to solid tumors. Erik earned a PhD in biomedical engineering from the University of Michigan and an MBA from Cornell University.
As head of the client success team at Endpoints News, Kari oversees campaign delivery and strategy for all advertising and client-directed webinars. She brings nearly 20 years of diverse experience across strategic communications, content development and operational leadership.